RNA profiling for individualized diet and treatment advice.

    公开(公告)号:US20200032347A1

    公开(公告)日:2020-01-30

    申请号:US16491165

    申请日:2018-03-07

    Abstract: The present invention relates to the field of medicine and molecular diagnostics. In particular, it relates to a novel RNA next generation sequencing-based profiling assay allowing simultaneous detection of transcripts and alternative splice variants thereof and mutations therein, from genes involved in disease. including genes involved in metabolism, resulting in an advice for personalized treatment with drugs targeting disease-associated molecular aberrations in combination with dietary compounds, food supplements or inhibitors of metabolism

    Noise reduction in image data
    112.
    发明申请

    公开(公告)号:US20190180419A1

    公开(公告)日:2019-06-13

    申请号:US16300091

    申请日:2017-05-15

    Abstract: A system for filtering an input image dataset is disclosed. A plurality of sequences of input signal values, wherein each sequence corresponds to a different attribute, wherein an input signal value is associated with an attribute and a sampling point i. At least one processor 4 is configured to control computing an output signal value corresponding to a sampling point and an attribute. For a particular sampling point i and for each of a plurality of different attributes of the set of attributes, associating a weight to an input signal value based on a similarity between the signal value and for a plurality of the sampling points j excluding the sampling point i. Also the system computes a weighted sum based on the input signal values and weights. The attribute is a location or a frequency.

    Polymer suitable for use in cell culture

    公开(公告)号:US10266809B2

    公开(公告)日:2019-04-23

    申请号:US14905579

    申请日:2014-07-16

    Abstract: A process for making an oligo(alkylene glycol) functionalized co-polyisocyanopeptide, wherein the process includes the steps of: i) copolymerizing a first comonomer of an oligo(alkylene glycol) functionalized isocyanopeptide grafted with a linking group and a second comonomer of a non-grafted oligo(alkylene glycol) functionalized isocyanopeptide, wherein the molar ratio between the first comonomer and the second comonomer is 1:500 and 1:30 and ii) adding a reactant of a spacer unit and a cell adhesion factor to the copolymer obtained by step i), wherein the spacer unit is represented by general formula A-L-B, wherein the linking group and group A are chosen to react and form a first coupling and the cell adhesion factor and group B are chosen to react and form a second coupling, wherein the first coupling and the second coupling are independently selected from the group consisting of alkyne-azide coupling, dibenzocyclooctyne-azide coupling, oxanorbornmadiene-based-azide couplings, vinylsulphone-thiol coupling, maleimide-thiol coupling, methyl methacrylate-thiol coupling, ether coupling, thioether coupling, biotin-strepavidin coupling, amine-carboxylic acid resulting in amides linkages, alcohol-carboxylic acid coupling resulting in esters linkages and NHS-Ester (N-Hydroxysuccinimide ester)-amine coupling and wherein group L is a linear chain segment having 10-60 bonds between atoms selected from C, N, O and S in the main chain.

    PROCESS FOR PREPARATION OF BEADS FOR IMAGING
    115.
    发明申请

    公开(公告)号:US20190077925A1

    公开(公告)日:2019-03-14

    申请号:US16083576

    申请日:2017-03-13

    Abstract: A process for the preparation of beads including a biocompatible hydrophobic polymer, a perfluorocarbon, polyvinylalcohol and optionally a metal compound, including the steps of: adding the perfluorocarbon and optionally the metal compound to a solution of the biocompatible hydrophobic polymer in a polar solvent to provide a first liquid mixture, adding the first liquid mixture to an aqueous solution of a biocompatible surfactant including polyvinylalcohol under sonication to obtain a second liquid mixture, a) maintaining the sonication of the second liquid mixture while cooling, b) evaporating the polar solvent from the second liquid mixture to obtain a suspension of beads including the biocompatible hydrophobic polymer, the perfluorocarbon and optionally the metal compound, c) separating the beads from the suspension and preparing a water suspension of the beads and d) freeze-drying the water suspension to obtain the beads, wherein the addition of the first liquid mixture to the biocompatible surfactant in step b) is performed within a period of at most 10 seconds, wherein the sonication in step b) and the sonication in step c) are performed directly into the liquid mixtures by for example a probe or flow sonicator at an amplitude of at least 120 μm for 0.01-10 minutes and wherein the weight ratio of the biocompatible surfactant to the biocompatible hydrophobic polymer is at least 3:1. Beads having close F-H2O interactions, which are suitable for imaging purposes.

    AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY

    公开(公告)号:US20180030035A1

    公开(公告)日:2018-02-01

    申请号:US15729267

    申请日:2017-10-10

    Abstract: A compound having the structure according to formula III wherein: X is NH or S; R1 is H or (1C-4C)alkyl; R2 is (1C-4C)alkyl, phenyl or a monocyclic aromatic ring having one or more N—, O— or S— atoms in the ring, which alkyl, phenyl or aromatic ring is optionally substituted with one or more groups selected from (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, phenyloxy, phenylthio, halogen, or nitro; R3 and R4 are each independently H, (1C-6C)alkyl, (2C-6C) alkenyl, (2C-6C)alkynyl, cyano, (3C-6C)cycloalkyl, phenyl, a monocyclic aromatic ring having one or more N—, O— or S— atoms in the ring, a monocyclic non-aromatic ring having one or more N—, O— or S— atoms in the ring, each optionally substituted with hydroxyl, (1C-4C)alkoxy, phenyl, cycloalkyl, piperidyl, piperazinyl, furyl, thienyl, pirazinyl, pyrrolyl, 2H-pyrrolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyrrolidonyl, pyrrolinyl, imidazolinyl, imidazolyl, a monocyclic aromatic ring having one or more N—, O— or S— atoms in the ring, whereby each of these optional substituents is optionally further substituted with (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, halogen, nitro or (1C-2C)dioxol forming a ring; or R3 and R4 form together pyrrolyl, imidazolyl, pyrazolyl, pyrrolidinyl, pyrrolinylimidazolidinyl, imidazolinyl, piperidyl, piperazinylmorpholinyl, each optionally substituted with (1C-6C)alkyl, phenyl(1C-4C)alkyl, phenylketo(1C-4C)alkyl; R5 is H, Cl, F, Br, Me, NO2, t-butyl, OCF3, OCH3, CF3; R6 is H, (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, nitro or halogen; R7 is H, F, Cl, Br, Me, NO2, t-butyl, OCF3, OCH3, CF3; or pharmaceutically acceptable addition salts thereof for use in treatments of carcinoma, in particular, to delay, prevent or reverse metastasis in prostate cancer.

Patent Agency Ranking